ClinicalTrials.gg
RecruitingNCT07013370Updated Jun 10, 2025

Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

An observational study in Immunoglobulin Prophylaxis, Cytomegalovirus Infections and Allogeneic Hematopoietic Stem Cell Transplantation, sponsored by Antonello Di Paolo, M.D., Ph.D.. Recruiting at 1 site in Italy. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2025-06-10.

Sponsored by Antonello Di Paolo, M.D., Ph.D. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
150
Ages
1 Month to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Cytomegalovirus Infections with a site in Italy — 5 open to participants now, 6 under way, 1 of them phase 3. Cytomegalovirus Infections · Italy.

Started
2025
with 1 other
Observational
4 of 18
3 open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
Antonello Di Paolo, M.D., Ph.D.

Among the 18 studies in Cytomegalovirus Infections with a site in Italy, this one is one of 2 that started in 2025, is one of 4 observational ones, and was the 18th registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

5 of the 18 studies in Cytomegalovirus Infections with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 1 Month to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Cytomegalovirus Infections with a site in Italy, or all of them as a file.
02

Study summary

Human cytomegalovirus (CMV) is a globally prevalent, human-specific herpesvirus characterised by a lifelong latency after primary infection, an often asymptomatic reactivation and affecting up to 100% of adults based on region and age. CMV reactivation has serious risks for immunocompromised patients, especially those undergoing allogeneic hematopoietic stem cell transplantation (HSCT). In these patients, CMV can lead to graft failure, multiorgan disease, increased risk of other infections, GVHD, post-transplant lymphoproliferative disorders, and higher transplant-related mortality (TRM). Although antiviral prophylaxis, CMV infection occurs in 38-80% of HSCT recipients, but current antiviral drugs are insufficiently effective and they are associated with adverse effects. Furthermore, treatment failure is due to the high genetic variability of CMV. The protective role of virus-specific antibodies remains under debate. Some studies suggest that high neutralizing antibody titers protect transplant recipients from CMV, while others highlight the importance of T-cell responses. However, recent animal studies showed that humoral immunity alone can prevent CMV reactivation, even without T or NK cells. In solid-organ transplant patients, antibody titers ≥480 have been linked to reduced infection, shorter treatment, and full protection from CMV disease. Although the use of anti-CMV immunoglobulin remains controversial, the IRCCS Burlo Garofolo has used it as post-transplant prophylaxis and second-line treatment for over a decade.

The main objective of their study was to assess whether CMV-specific immunoglobulin prophylaxis reduces CMV incidence and severity in pediatric HSCT patients. Secondary goals included evaluating its effect on transplant outcomes and its efficacy across different ethnic groups. A population pharmacokinetic (POP/PK) study was also conducted to better understand the drug's distribution and elimination and to identify factors influencing its pharmacokinetics in patients.

Read the detailed description

The study will enroll all patients who received standard myeloablative conditioning. GVHD prophylaxis consisting of tacrolimus and, for unrelated donors, rabbit ATG and mycophenolate mofetil. Haploidentical transplants initially used in vivo T-cell depletion with post-transplant cyclophosphamide, later replaced by ex vivo αβ+/CD19+ T-cell depletion.

Outcomes included overall survival (OS), relapse-related mortality (RRM), and GVHD, defined by standard grading systems. Immune reconstitution was measured by CD4+ T-lymphocyte counts, with ≥500 cells/μL in two readings within 100 days post-HSCT considered adequate. Follow-up continued until death or last contact, with a minimum duration of 12 months for survivors.

Viral Load Detection

CMV DNAemia was quantified in whole blood using real-time PCR (CMV ELITe MGB Kit). Monitoring occurred twice weekly during hospitalization, then weekly in outpatient visits until immune reconstitution and end of immunosuppression.

CMV-Specific Immunoglobulin Prophylaxis and Treatment

Prophylaxis was administered using Cytomegatect® (Biotest Pharma GmbH), beginning on day 3 of conditioning and continued biweekly during hospitalization. Post-discharge, it was given at each hospital admission until CD4+ normalization. If DNAemia appeared, a 3-5 day "boost" treatment was given based on risk assessment. Non-responders (based on viral load behavior) discontinued treatment. In cases of CMV disease, dosing and treatment duration were tailored. Cytomegatect was dosed by weight: 1000 U (\<10 kg), 2000 U (10-25 kg), 3000 U (25-50 kg), and 4000 U (>50 kg).

Foscarnet was used as first-line therapy within the first post-transplant month. Ganciclovir or valganciclovir was introduced after engraftment. Second-line options included cidofovir, letermovir, and maribavir. Advanced therapies involved NK or CD45RO+ lymphocyte infusions. CMV IgG levels were monitored 24-72 hours after each infusion for inpatients and before administration for outpatients.

CMV-Related Complications

CMV-related complications were classified per Ljungman et al.'s updated definitions. CMV infection referred to virus detection in body fluids or tissues. DNAemia denoted CMV DNA presence in blood. Primary infection was the first detection in previously unexposed patients; recurrent infections occurred after a 4-week CMV-negative interval. Refractory infections showed persistent or increasing viral load despite at least two weeks of treatment. CMV disease followed existing consensus criteria.

Statistical and POP/PK Analyses

Continuous variables were summarized by means or medians with interquartile ranges, depending on distribution (tested via Shapiro-Wilk). Categorical variables were presented as counts and percentages. Group comparisons were performed using chi-square tests for qualitative variables and Wilcoxon tests for continuous ones. Kaplan-Meier curves and log-rank tests assessed survival outcomes. Differences in pharmacokinetics between occasions were evaluated with ANOVA.

Plasma concentrations of anti-CMV immunoglobulin were analyzed using a nonlinear mixed-effects modeling approach via Monolix 2023.1. Mono-, bi-, and tri-compartmental models with various error structures were evaluated. Covariates (age, weight, creatinine clearance) were assessed for influence on model performance, which was judged based on objective function value (OFV), standard errors, and residual distributions. Individual elimination half-lives were calculated as t½ = (0.693 × Vi) / Cli, where Vi and Cli are individual volume of distribution and clearance values

03

Conditions studied

  • Immunoglobulin Prophylaxis
  • Cytomegalovirus Infections
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Transplant-Related Disorder

Keywords

  • Cytomegalovirus
  • allo-HSCT
  • Transplant-Related mortality
04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Children who underwent allogeneic HSCT due to any condition

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children who underwent HSCT due to any condition

Exclusion criteria

Exclusion Criteria:

  • Positive personal records of immunoglobulin-related adverse reactions
  • CMV reactivation before the CMV-specific immunoglobulin prophylaxis onset
  • adoptive cellular post- immunotherapy for any indication
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Control Group

    Pediatric allo-HSCT recipients who have not received CMV-specific immunoglobulin prophylaxis after transplantation.

  • Immunoprophylaxis Group

    Pediatric allo-HSCT recipients who received an anti-CMV prophylaxis with immunoglobulin (Megalotect)

    Biological: Anti-CMV immunoglobulins [Megalotect (R)]

Interventions

  • BiologicalAnti-CMV immunoglobulins [Megalotect (R)]

    Children received an anti-CMV immunoglobulin to prevent viral infections

06

What researchers measure

Primary outcomes

  1. CMV reactivation and infection

    The rate of viral reactivation and infection in children undergoing all-HSCT

    Time frame: 12 months since allo-HSCT

Secondary outcomes

  1. Overall Survival

    The rate of overall survival since allo-HSCT

    Time frame: 12 months since allo-HSCT

  2. Hospital stay

    The lenght of hospital stay after allo-HSCT

    Time frame: 12 months since allo-HSCT

  3. Immunological recovery

    The percentage of patients in who the function of CD4+ lymphocytes was restored

    Time frame: 12 months since allo-HSCT

  4. GVHD incidence

    The percentage of patients who experienced a GVHD

    Time frame: 12 months since allo-HSCT

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Data sharing will be discussed case by case upon reasonable request and after local IRB approval.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Dec 2025, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Jun 10, 2025
StartActual
Jun 2, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jun 2, 2026
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07013370
Lead sponsor
Antonello Di Paolo, M.D., Ph.D.
Collaborators
IRCCS Burlo Garofolo
Responsible party
Antonello Di Paolo, M.D., Ph.D. (Assistant Professor of Pharmacology, University of Pisa) — Sponsor-investigator
First posted
Jun 10, 2025
Start date
Jun 2, 2025
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 2, 2026 (estimated)
Last update
Jun 10, 2025

Study contacts

Natalia Maximova, MD
Contact
natalia.maximova@burlo.trieste.it
+39-040.3785.111 ext. .565
Debora Curci, PhD
Contact
debora.curci@burlo.trieste.it
+39-040.3785.111
Natalia Maximova, MD
principal investigator · IRCCS Burlo Garofolo - Trieste - ITALY

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion